Results 21 to 30 of about 105,114 (279)

Histone acetyltransferase 1 promotes gemcitabine resistance by regulating the PVT1/EZH2 complex in pancreatic cancer

Cell Death and Disease, 2021
The poor prognosis of pancreatic cancer is primarily due to the development of resistance to therapies, including gemcitabine. The long noncoding RNA PVT1 (lncRNA PVT1) has been shown to interact with enhancer of zeste 2 polycomb repressive complex 2 ...
Yan Sun, Dianyun Ren, Yingke Zhou, Jian Shen, Heshui Wu, Xin Jin   +5 more
doaj   +1 more source

Correction to "Preoperative Gemcitabine/Nab-Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer: A Comparative Analysis With Preoperative Chemoradiation Therapy Using Gemcitabine Alone". [PDF]

Ann Gastroenterol Surg
Annals of Gastroenterological Surgery, EarlyView.
europepmc   +2 more sources

Gemcitabine: Progress in the treatment of pancreatic cancer [PDF]

, 2001
Unresectable pancreatic cancer has a dismal prognosis with a median survival of 3-5 months in untreated disease. Since the introduction of gemcitabine, pancreatic cancer may no longer be regarded a chemotherapy-resistant tumor.
Heinemann, Volker
core   +1 more source

Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors

Journal of Pharmacological Sciences, 2015
Gemcitabine is widely used for pancreatic, lung, and bladder cancer. However, drug resistance against gemcitabine is a large obstacle to effective chemotherapy. Nucleoside transporters, nucleoside and nucleotide metabolic enzymes, and efflux transporters
Kentaro Minami, Yoshinari Shinsato, Masatatsu Yamamoto, Homare Takahashi, Shaoxuan Zhang, Yukihiko Nishizawa, Sho Tabata, Ryuji Ikeda, Kohich Kawahara, Kazutake Tsujikawa, Kazuo Chijiiwa, Katsushi Yamada, Shin-ichi Akiyama, Sandra Pérez-Torras, Marcal Pastor-Anglada, Tatsuhiko Furukawa, Takeda Yasuo   +16 more
doaj   +1 more source

Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer

Molecular Cancer, 2022
Background Although gemcitabine has been considered as the first-line drug for advanced pancreatic cancer (PC), development of resistance to gemcitabine severely limits the effectiveness of this chemotherapy, and the underlying mechanism of gemcitabine ...
Jianyou Gu, Wenjie Huang, Xianxing Wang, Junfeng Zhang, Tian Tao, Yao Zheng, Songsong Liu, Jiali Yang, Zhe-Sheng Chen, Chao-Yun Cai, Jinsui Li, Huaizhi Wang, Yingfang Fan   +12 more
doaj   +1 more source

Role of gemcitabine in the treatment of advanced and metastatic breast cancer [PDF]

, 2003
Gemcitabine is an antimetabolite drug with proven antitumor activity and tolerability in metastatic breast cancer. In a total of nine studies, gemcitabine monotherapy has reached response rates of up to 37% in the first-line setting, 26% in the second ...
Heinemann, Volker
core   +1 more source

Pharmacogenomics and gemcitabine

Annals of Oncology, 2006
Approximately half of lung cancer patients present with metastases, and a large proportion will develop recurrent disease, with median survival to cisplatin-based chemotherapy of 11 months. No predictive factor of response to cisplatin-based chemotherapy is yet available in clinical practice.
R, Rosell, M, Cobo, D, Isla, C, Camps, B, Massuti   +4 more
openaire   +2 more sources

Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer [PDF]

, 2007
Background: Patients with metastatic breast cancer (MBC) are increasingly exposed to anthracyclines and taxanes either during treatment of primary breast cancer or during initial therapy of metastatic disease.
Vehling-Kaiser, U., Melchert, F., Koelbl, H., Maubach, P., Stemmler, H. J., Scharl, A., Heinemann, Volker, Weber, B., Meerpohl, H., Kalischefski, B., Laessig, D., Stauch, M., Morack, G., Fasching, P. A.   +13 more
core   +1 more source

A rapid and systematic review of the clinical effectiveness and cost effectiveness of gemcitabine for the treatment of pancreatic cancer [PDF]

, 2001
Background Pancreatic cancer is the eighth most common cancer in the UK and the sixth most common cause of cancer death; in 1998, 3198 men and 3364 women died from this condition. In an average health authority with a population of 500,000, there
Calvert, N, Larvin, M., E. Morris, Bansback, N., Bansback, N, D. Radstone, Morris, E., D. Forman (12595714), A. Crellin (12595711), S. Ward (7130246), Forman, D., E. Morris (7786319), N. Calvert, Calvert, N., D. Radstone (12595720), Crellin, A., Larvin, M, Morris, E, D. Forman, Ward, S., A. Crellin, Radstone, D, S. Ward, N. Calvert (12595708), M. Larvin, N. Bansback (12595705), Forman, D, Ward, S, N. Bansback, Michael Larvin (12595717), Crellin, A   +30 more
core   +1 more source

Stearoyl-CoA desaturase 1 inhibitor supplemented with gemcitabine treatment reduces the viability and fatty acid content of pancreatic cancer cells in vitro

Journal of Pancreatology, 2021
. Objective:. Pancreatic cancer (PC) is an aggressive cancer with ineffective treatment. Inhibition of stearoyl-CoA desaturase 1 (SCD1) suppresses cancer proliferation and might act as a novel chemotherapy supplement, but this has not been investigated ...
Amon B. Hackney, Wen Y. Chung, John Isherwood, Ashley R. Dennison, Naomi Martin   +4 more
doaj   +1 more source